See more : Investor AB (INVEAS.XD) Income Statement Analysis – Financial Results
Complete financial analysis of DiaMedica Therapeutics Inc. (DMAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DiaMedica Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wheaton Precious Metals Corp. (WPM.TO) Income Statement Analysis – Financial Results
- BES Engineering Corporation (2515.TW) Income Statement Analysis – Financial Results
- Nakano Refrigerators Co.,Ltd. (6411.T) Income Statement Analysis – Financial Results
- Kinepolis Group NV (KIN.BR) Income Statement Analysis – Financial Results
- Successmore Being Public Company Limited (SCM.BK) Income Statement Analysis – Financial Results
DiaMedica Therapeutics Inc. (DMAC)
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Cost of Revenue | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 0.00 | 4.00K | 2.21K | 4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -30.00K | -25.00K | -24.00K | -21.00K | -21.00K | 500.00K | -4.00K | -2.21K | -4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 13.11M | 7.84M | 8.77M | 8.31M | 7.90M | 4.52M | 3.21M | 1.76M | 886.07K | 3.71M | 3.78M | 5.21M | 2.33M | 803.98K | 1.37M | 1.04M | 1.07M | 617.26K | 22.75K | 462.00K |
| General & Administrative | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 1.38M | 192.37K | 177.78K | 168.91K |
| Other Expenses | 0.00 | 353.00K | 82.00K | -205.00K | -856.00K | -68.00K | 6.00K | 221.90K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.58K | -4.89K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Cost & Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.73K | 1.74K | 10.54K | 14.73K | 41.03K | 51.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.38K | 43.96K | 0.00 | 7.73K | 2.72K | 12.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.60K | 36.59K |
| Depreciation & Amortization | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 15.00K | 4.00K | 2.21K | 4.11K | 2.47K | 1.11M | 2.37M | 2.30M | 1.67M | 30.20K | 26.74K | 18.35K | 3.32K | 28.15K | 6.41K |
| EBITDA | -19.31M | -13.98M | -13.62M | -12.24M | -10.60M | -5.64M | -4.26M | -2.15M | -1.50M | -5.01M | -6.51M | -7.70M | -4.51M | -3.32M | -2.27M | -2.34M | -2.29M | -783.89K | -190.26K | -630.30K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,098.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.62% | -3,045.78% | -680.92% | -1,762.12% |
| Operating Income | -21.27M | -14.00M | -13.65M | -12.70M | -11.59M | -6.76M | -4.52M | -2.48M | -1.31M | -4.83M | -7.43M | -10.11M | -6.71M | -3.84M | -2.40M | -1.69M | -2.31M | -787.21K | -203.01K | -603.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,352.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,438.05% | -3,058.67% | -790.56% | -1,781.04% |
| Total Other Income/Expenses | 1.93M | 353.00K | 82.00K | 434.00K | 975.00K | 747.00K | 259.00K | 280.63K | -104.38K | -185.41K | -230.99K | 37.57K | -174.26K | -422.84K | 101.28K | -168.32K | 57.19K | -12.38K | 10.28K | 66.55K |
| Income Before Tax | -19.34M | -13.65M | -13.56M | -12.27M | -10.62M | -5.65M | -4.26M | -2.20M | -1.43M | -4.78M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.31M | 0.00 | -192.73K | -570.16K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,130.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,440.21% | 0.00% | -750.53% | -1,682.83% |
| Income Tax Expense | 43.00K | 28.00K | 28.00K | 27.00K | 31.00K | 80.00K | -9.00K | 22.31K | 12.45K | 42.28K | 7.73K | 2.72K | 12.57K | 499.08K | 41.69K | 163.43K | 20.20K | -9.19K | 17.87K | 69.86K |
| Net Income | -19.38M | -13.68M | -13.59M | -12.29M | -10.65M | -5.73M | -4.26M | -2.22M | -1.44M | -4.82M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.33M | -778.02K | -210.60K | -640.02K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,452.78% | -3,022.96% | -820.13% | -1,889.02% |
| EPS | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| EPS Diluted | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| Weighted Avg Shares Out | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
| Weighted Avg Shares Out (Dil) | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak -...
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended June 30, 2023. Management will host a...
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close...
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced the company will be attending the 2023 AAN Summer Conference on July 28-29, at the Minneapolis Hyatt Regency. This year's...
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023. Dr. Richard Kuntz recently...
DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street...
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close...
DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Kirsten Gruis - Chief Medical Officer Conference Call...
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on...
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33rd...
Source: https://incomestatements.info
Category: Stock Reports